NASDAQ · CELUW
Healthcare · Biotechnology
$0.00
Up+$0.00 (+533.33%)
Updated Sep 20, 2026, 8:33 PM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CELUW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CELUW.
CELUW research
Company profile and research snapshot.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
GlobeNewswire Inc. · Aug 22, 2025
Celularity received a Nasdaq notification for not timely filing its Quarterly Report on Form 10-Q for June 30, 2025, potentially risking its listing compliance, with a deadline of September 5, 2025 to submit a compliance plan.
GlobeNewswire Inc. · Apr 25, 2025
Celularity Inc. (CELU) received a Nasdaq delisting notice due to unpaid fees and a delinquent SEC filing. The company paid the outstanding fees and is working to file the 2024 Form 10-K.
GlobeNewswire Inc. · Apr 14, 2025
Celularity welcomes CMS action to delay the effective date of a Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers from February 2025 to January 2026, ensuring continued access to these critical wound care products for Medicare patients.
GlobeNewswire Inc. · Dec 10, 2024
Celularity Inc. has regained compliance with Nasdaq listing rules after addressing a backlog of financial filings. The company has implemented process improvements, including engaging a new audit firm, to ensure timely and accurate reporting going forward.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CELUW.
No results
No recent SID articles mention CELUW.
